Drug Patents owned by Supernus Pharms

1. List of Oxtellar Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7722898 SUPERNUS PHARMS Modified-release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US9370525 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US8617600 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US10220042 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US9119791 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US7910131 SUPERNUS PHARMS Method of treating seizures using modified release formulations of oxcarbazepine
Apr, 2027

(4 years from now)

US9855278 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US11166960 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US8821930 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US9351975 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

Drugs and Companies using OXCARBAZEPINE ingredient

Market Authorisation Date: 19 October, 2012

Treatment: Treatment of partial-onset seizures

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of OXTELLAR XR before it's patent expiration?
More Information on Dosage

2. List of Qelbree drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324753 SUPERNUS PHARMS Method of treatment of attention deficit/hyperactivity disorder (ADHD)
Sep, 2029

(6 years from now)

US11458143 SUPERNUS PHARMS NA
Sep, 2029

(6 years from now)

US9358204 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(10 years from now)

US9603853 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(10 years from now)

US9662338 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 2, 2026
New Patient Population (NPP) Apr 29, 2025

Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient

NCE-1 date: April, 2025

Market Authorisation Date: 02 April, 2021

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); U-727: for the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

3. List of Trokendi Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8298580 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US9555004 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US10314790 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US9622983 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8877248 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8663683 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8992989 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8889191 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US9549940 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8298576 SUPERNUS PHARMS Sustained-release formulations of topiramate
Apr, 2028

(5 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 16 August, 2013

Treatment: Use of trokendi xr for prophylactic treatment of migraine; Treatment of epilepsy; Use of trokendi xr for the treatment of epilepsy

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of TROKENDI XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in